These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 21338040)

  • 1. Emerging oral therapies for multiple sclerosis.
    Miller CE; Umhauer MA
    J Neurosci Nurs; 2011 Feb; 43(1):3-14; quiz 15-6. PubMed ID: 21338040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New and emerging disease modifying therapies for multiple sclerosis.
    Saidha S; Eckstein C; Calabresi PA
    Ann N Y Acad Sci; 2012 Jan; 1247():117-37. PubMed ID: 22224673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging oral agents for multiple sclerosis.
    Fox EJ
    Am J Manag Care; 2010 Sep; 16(8 Suppl):S219-26. PubMed ID: 20873946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.
    Sørensen PS
    J Neurol Sci; 2011 Dec; 311 Suppl 1():S29-34. PubMed ID: 22206763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging disease-modifying oral therapies for multiple sclerosis.
    Losy J; Kalinowska-Łyszczarz A
    J Neuroimmunol; 2011 Feb; 231(1-2):15-22. PubMed ID: 20947176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Principles of a new treatment algorithm in multiple sclerosis.
    Hartung HP; Montalban X; Sorensen PS; Vermersch P; Olsson T
    Expert Rev Neurother; 2011 Mar; 11(3):351-62. PubMed ID: 21375441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple sclerosis: managing a complex neurological disease.
    Embrey N
    Nurs Stand; 2014 Nov; 29(11):49-58. PubMed ID: 25388738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Currently approved and emerging oral therapies in multiple sclerosis: An update for the ophthalmologist.
    Eckstein C; Bhatti MT
    Surv Ophthalmol; 2016; 61(3):318-32. PubMed ID: 26703886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of delayed diagnosis and treatment in clinically isolated syndrome and multiple sclerosis.
    Kennedy P
    J Neurosci Nurs; 2013 Dec; 45(6 Suppl 1):S3-13. PubMed ID: 24217189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How much progress has there been in the second-line treatment of multiple sclerosis: A 2017 update.
    Maarouf A; Boutière C; Rico A; Audoin B; Pelletier J
    Rev Neurol (Paris); 2018 Jun; 174(6):429-440. PubMed ID: 29779849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Established and novel disease-modifying treatments in multiple sclerosis.
    Cross AH; Naismith RT
    J Intern Med; 2014 Apr; 275(4):350-63. PubMed ID: 24444048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral drugs in multiple sclerosis therapy: an overview and a critical appraisal.
    D'Amico E; Leone C; Caserta C; Patti F
    Expert Rev Neurother; 2015; 15(7):803-24. PubMed ID: 26098146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
    Wingerchuk DM; Carter JL
    Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The New England Journal of Medicine publishes pivotal data demonstrating efficacy and safety of oral BG-12 (dimethyl fumarate) in multiple sclerosis.
    Fox R
    Can J Neurosci Nurs; 2012; 34(3):7-11. PubMed ID: 23362583
    [No Abstract]   [Full Text] [Related]  

  • 15. Present and emerging therapies for multiple sclerosis.
    Freedman MS
    Continuum (Minneap Minn); 2013 Aug; 19(4 Multiple Sclerosis):968-91. PubMed ID: 23917096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging oral drugs for relapsing-remitting multiple sclerosis.
    Gasperini C; Ruggieri S
    Expert Opin Emerg Drugs; 2011 Dec; 16(4):697-712. PubMed ID: 22148963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Copolymer-1 in the treatment of multiple sclerosis.
    Boyden KM
    J Neurosci Nurs; 1998 Apr; 30(2):135-9; quiz 140-1. PubMed ID: 9642622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple sclerosis therapeutic pipeline: opportunities and challenges.
    Krieger S
    Mt Sinai J Med; 2011; 78(2):192-206. PubMed ID: 21425264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recognizing and overcoming potential barriers to oral medications for MS.
    Moses H
    J Clin Psychiatry; 2014 Oct; 75(10):e28. PubMed ID: 25373133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple sclerosis in childhood: understanding and caring for children with an "adult" disease.
    Boyd JR; MacMillan LJ
    Axone; 2000 Dec; 22(2):15-21. PubMed ID: 11901486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.